EP3820482A4 - TUMOR REDUCING AGENT FORMULATIONS AND METHODS OF USE THEREOF - Google Patents

TUMOR REDUCING AGENT FORMULATIONS AND METHODS OF USE THEREOF Download PDF

Info

Publication number
EP3820482A4
EP3820482A4 EP19841949.1A EP19841949A EP3820482A4 EP 3820482 A4 EP3820482 A4 EP 3820482A4 EP 19841949 A EP19841949 A EP 19841949A EP 3820482 A4 EP3820482 A4 EP 3820482A4
Authority
EP
European Patent Office
Prior art keywords
methods
tumor reduction
formulations
reduction formulations
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19841949.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3820482A1 (en
Inventor
Steven Hoffman
John Rothman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tyme Inc
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of EP3820482A1 publication Critical patent/EP3820482A1/en
Publication of EP3820482A4 publication Critical patent/EP3820482A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP19841949.1A 2018-07-09 2019-07-02 TUMOR REDUCING AGENT FORMULATIONS AND METHODS OF USE THEREOF Withdrawn EP3820482A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (2)

Publication Number Publication Date
EP3820482A1 EP3820482A1 (en) 2021-05-19
EP3820482A4 true EP3820482A4 (en) 2022-03-23

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19841949.1A Withdrawn EP3820482A4 (en) 2018-07-09 2019-07-02 TUMOR REDUCING AGENT FORMULATIONS AND METHODS OF USE THEREOF

Country Status (11)

Country Link
EP (1) EP3820482A4 (ru)
JP (1) JP2021530482A (ru)
KR (1) KR20220098082A (ru)
CN (1) CN112584841A (ru)
AU (1) AU2019309757A1 (ru)
BR (1) BR112021000279A8 (ru)
CA (1) CA3105717A1 (ru)
EA (1) EA202190201A1 (ru)
IL (1) IL280000A (ru)
PH (1) PH12021550033A1 (ru)
WO (1) WO2020023191A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
IL293706A (en) * 2019-12-09 2022-08-01 Tyme Inc Pharmacy preparations and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306137A1 (en) * 2006-02-20 2008-12-11 Beijing Century Biocom Pharmaceutical Technology Co., Ltd. Pharmaceutical compositions comprising docetaxel and methods for preparation thereof
WO2017160895A1 (en) * 2016-03-15 2017-09-21 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060135729A (ko) * 2004-01-29 2006-12-29 백스터 인터내셔널 인코포레이티드 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
AU2015287749B2 (en) * 2014-07-11 2021-03-11 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306137A1 (en) * 2006-02-20 2008-12-11 Beijing Century Biocom Pharmaceutical Technology Co., Ltd. Pharmaceutical compositions comprising docetaxel and methods for preparation thereof
WO2017160895A1 (en) * 2016-03-15 2017-09-21 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020023191A1 *

Also Published As

Publication number Publication date
CN112584841A (zh) 2021-03-30
EA202190201A1 (ru) 2021-04-09
BR112021000279A2 (pt) 2021-04-06
AU2019309757A1 (en) 2021-03-04
PH12021550033A1 (en) 2021-09-20
JP2021530482A (ja) 2021-11-11
KR20220098082A (ko) 2022-07-11
EP3820482A1 (en) 2021-05-19
IL280000A (en) 2021-03-01
CA3105717A1 (en) 2020-01-30
WO2020023191A1 (en) 2020-01-30
CN112584841A8 (zh) 2021-06-18
BR112021000279A8 (pt) 2021-04-20

Similar Documents

Publication Publication Date Title
EP3775203A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
EP3790596A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
EP3684364A4 (en) PYRIDAZINONE AND METHOD OF USE THEREOF
EP3894392A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3749344A4 (en) METHODS OF THERAPEUTIC USE OF EXOSOMES AND YRNA
EP3873387A4 (en) BODY ENGAGEMENT DEVICES AND METHODS OF USE
EP3852533B8 (en) Pyridazinones and methods of use thereof
EP3886853A4 (en) DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF
EP3752166A4 (en) TRIALCYNE BINDING AGENTS AND METHODS OF USE
EP3740576A4 (en) THERAPEUTIC COMPOSITIONS AND THEIR PREPARATION AND USE METHODS
EP3638331A4 (en) THREE-DIMENSIONAL FABRIC COMPOSITIONS AND METHODS OF USE
EP3870203A4 (en) THERAPEUTIC COMBINATIONS OF TDFRP AND COMPLEMENTARY AGENTS AND METHODS OF USE
IL280000A (en) Formulations for reducing tumors and methods of using them
EP3829307A4 (en) BISMUTH-THIOL COMPOSITIONS AND METHODS OF USE
EP3678701A4 (en) THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
EP3784148A4 (en) IMPLANTS, USE AND ASSEMBLY PROCEDURES
EP3758633A4 (en) IMPLANTS AND METHODS OF USE AND ASSEMBLY
EP3675871A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF FIBROTIC DISEASES
EP3941475A4 (en) PYRIDAZINONES AND THEIR METHODS OF USE
EP3960766A4 (en) ANTI-TUMOR THERAPEUTIC AGENT AND USE THEREOF
EP3761989A4 (en) IMIDAZODIAZEPINEDIONES AND THEIR METHODS FOR USE
EP4037715A4 (en) PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE
EP3810118A4 (en) FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
AU2018292381A1 (en) Cosmetic compositions and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220223

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20220217BHEP

Ipc: A61K 47/28 20060101ALI20220217BHEP

Ipc: A61K 47/22 20060101ALI20220217BHEP

Ipc: A61K 47/10 20170101ALI20220217BHEP

Ipc: A61K 45/06 20060101ALI20220217BHEP

Ipc: A61K 31/575 20060101ALI20220217BHEP

Ipc: A61K 9/00 20060101ALI20220217BHEP

Ipc: A61K 31/4015 20060101ALI20220217BHEP

Ipc: A61K 31/08 20060101ALI20220217BHEP

Ipc: A61K 38/17 20060101ALI20220217BHEP

Ipc: A61K 38/00 20060101ALI20220217BHEP

Ipc: A61K 31/7088 20060101AFI20220217BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230310